# Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

> **NCT00336791** · PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 273 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** 5-Fluorouracil
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Paclitaxel
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT00336791
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2007-08
- **Final completion:** 2010-09
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2012-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00336791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00336791, "Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00336791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*